Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation Development

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation DevelopmentAuthor of the article:Combining formulation expertise and predictive modeling to make smarter development decisions earlier and reduce clinical development risk.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountLAVAL, Quebec — Corealis Pharma (“Corealis”) and PhinC Group (“PhinC”) have announced a strategic collaboration to integrate physiologically based biopharmaceutics modeling (PBBM) and physiologically based pharmacokinetic (PBPK) modeling directly into oral solid dosage form development.The collaboration brings together Corealis’ formulation and manufacturing expertise with PhinC Group’s predictive biopharmaceutics modeling capabilities to provide earlier insight into how formulation properties may influence clinical performance. The approach is particularly well suited to development-stage oral small-molecule programs where solubility limitations, release-profile optimisation, food effects, formulation bridging, or bioavailability uncertainty can significantly influence development strategy.“Too often, formulation decisions are made with limited visibility into how a drug product will ultimately perform in patients. By integrating PhinC’s predictive modeling capabilities with Corealis’ formulation and manufacturing expertise, we can evaluate critical development questions earlier, focus resources on the most promising approaches, and help our clients advance toward the clinic with greater confidence, stronger scientific rationale and reduced development risk,” said David Leroux-Petersen, CEO of Corealis Pharma.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againThe integrated approach uses API, formulation and dissolution data within PBBM/PBPK models to evaluate key factors such as release rate, solubility, particle size and food effects, guiding targeted prototype development and formulation selection.For biotech companies, the result is a more focused development strategy with the potential to reduce experimental iterations, generate earlier insight into human performance, prioritise formulation risks and increase confidence before committing valuable API, time and clinical resources.“The value of modeling is greatest when it informs development decisions,” said Samia Ezzine, Chief Scientific Officer, North America at PhinC Group. “Working with Corealis allows us to connect formulation characteristics to predicted human exposure and focus on the experiments that matter most.”Together, Corealis and PhinC aim to enable a more predictive, science-driven approach to formulation development, helping sponsors make critical development decisions earlier and with greater confidence.is a specialized oral solid dosage (OSD) CDMO supporting pharmaceutical and biotechnology companies from early formulation development through GMP clinical manufacturing and clinical supply. With integrated formulation, analytical and manufacturing capabilities, Corealis helps development-stage programs advance efficiently toward the clinic through science-driven formulation strategies, flexible manufacturing and experienced project execution. For more information, visitspecializes in model-informed drug development, applying advanced pharmacometric approaches including PBPK and PBBM to support drug development decision-making. By integrating drug, formulation and physiological data into predictive models, PhinC helps pharmaceutical and biotechnology companies better understand drug performance, anticipate clinical outcomes and make more informed development decisions. Learn more atView source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.